Eli Lilly's Diabetes and Obesity Drugs Lead to Significant Weight Loss.
TL;DR Summary
Eli Lilly's drug tirzepatide helped obese patients with Type 2 diabetes lose an average of 15% of their body weight, or about 34 pounds, in a late-stage clinical trial. The drug is already sold under the brand name Mounjaro for Type 2 diabetes and was found to be effective as a weight loss aid in a previous trial. The drug is a GLP-1 agonist, which mimics a hormone that helps reduce food intake and appetite. The FDA is currently reviewing tirzepatide for use as a weight loss aid in people with obesity or who are overweight.
- People with diabetes lost up to 34 pounds taking Eli Lilly drug, company says NBC News
- New obesity drug Mounjaro poised to surpass Ozempic, Wegovy The Associated Press
- Eli Lilly releases more data for new obesity drug, moving toward fast-track approval NPR
- Blood sugar drug tirzepatide also leads to substantial weight loss in diabetes patients, Eli Lilly says CNN
- Mounjaro Helps Diabetes Patients Lose 'Meaningful' Weight, Study Shows The Wall Street Journal
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
2 min
vs 3 min read
Condensed
84%
592 → 96 words
Want the full story? Read the original article
Read on NBC News